Merck's Earnings Beat Potential Overshadows Persistent Quality and Growth Risks, Analysts Urge Patience

What happened

A Seeking Alpha article argues that Merck's 1Q26 Street EPS estimate is understated by $3.29 per share, suggesting a high probability of beating consensus due to superior Core Earnings analysis. This contrasts sharply with the DeepValue master report, which maintains a WAIT rating citing $14.8 billion in acquisition accounting charges that distort reported profitability and elevate earnings-quality risks. Merck's strategy to bridge the Keytruda loss-of-exclusivity window through new launches like WINREVAIR and formulation switching via KEYTRUDA QLEX is acknowledged, but the report stresses the need for concrete evidence in the next 6-9 months. The article's focus on short-term earnings optimism may overlook the persistent noise from transaction-related adjustments, which DeepValue highlights as a cap on valuation multiples. Therefore, while a beat is possible, the underlying investment case hinges on durable growth metrics and charge containment, which remain unproven and warrant caution.

Implication

A beat in 1Q26 EPS could provide temporary stock momentum, but it fails to resolve the structural noise from acquisition charges that undermine earnings transparency. The DeepValue report emphasizes that without proof of WINREVAIR's durability and KEYTRUDA QLEX adoption, the long-term bridge to offset Keytruda LOE remains fragile and uncertain. Monitoring whether 2026 becomes a peak-charge year is critical, as additional adjustments could suppress valuation multiples and erode investor confidence. The WAIT rating advises patience for Q2-Q3 2026 updates to validate the transition strategy with operational milestones rather than earnings optics. Therefore, a prudent approach is to await clearer signals on growth sustainability and charge containment before considering entry, avoiding overreliance on short-term surprises.

Thesis delta

The article's claim of understated EPS estimates introduces a near-term bullish catalyst, but it does not shift the fundamental thesis due to unaddressed earnings-quality and growth sustainability risks. DeepValue's call to wait for evidence of durable growth and reduced transition noise remains unchanged, reinforcing the need for patience amid ongoing acquisition-related uncertainties.